The tumor suppressor protein p53 is inactivated in themajorityof human cancers and remains a prime target for developing new drugsto reactivate its tumor suppressing activity for anticancer therapies.The oncogenic p53 mutant Y220C accounts for approximately 125,000new cancer cases per annum and is one of the most prevalent p53 mutantsoverall. Here, TP53 is linked to neoplasm.